IPIAD augments commonplace remedy for pancreatic ductal adenocarcinoma

A brand new analysis perspective was revealed in Oncoscience (Quantity 11) on February 7, 2024, entitled, “IPIAD- an augmentation routine added to plain remedy of pancreatic ductal adenocarcinoma utilizing already-marketed repurposed medication irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.”

On this new paper, researcher Richard E. Kast from IIAIGC Examine Heart presents the info and rationale for including 5 generic non-oncology medication from basic medical follow to gemcitabine, nab-paclitaxel, a present commonplace cytotoxic chemotherapy of pancreatic ductal adenocarcinoma. The routine, known as IPIAD, makes use of an angiotensin receptor blocker (ARB) irbesartan indicated for treating hypertension, an previous antimicrobial drug pyrimethamine indicated for treating toxoplasmosis or malaria, an previous antifungal drug itraconazole, an previous broad spectrum antibiotic azithromycin, and an previous antibiotic dapsone. 

“In reviewing chosen progress driving programs lively in pancreatic ductal adenocarcinoma then evaluating these with detailed information on ancillary attributes of the IPIAD medication, one can predict scientific profit and slowing progress of pancreatic ductal adenocarcinoma by this augmentation routine.”